GB Sciences Inc (GBLX.PK)
GBLX.PK on OTC Markets Group
0.47USD
22 Jun 2018
0.47USD
22 Jun 2018
Change (% chg)
$-0.03 (-5.78%)
$-0.03 (-5.78%)
Prev Close
$0.49
$0.49
Open
$0.49
$0.49
Day's High
$0.50
$0.50
Day's Low
$0.46
$0.46
Volume
465,723
465,723
Avg. Vol
628,853
628,853
52-wk High
$1.56
$1.56
52-wk Low
$0.21
$0.21
About
GB Sciences, Inc., formerly Growblox Sciences, Inc., is engaged in developing and utilizing technologies in plant biology, cultivation and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates and cannabinoid therapies. It seeks to be a technology and solution... (more)
No analyst recommendations are available for .
Overall
| Beta: | -0.21 |
| Market Cap(Mil.): | $31.94 |
| Shares Outstanding(Mil.): | 127.75 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| GBLX.PK | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 9.16 | 40.93 |
| EPS (TTM): | -0.12 | -- | -- |
| ROI: | -189.49 | 8.30 | 62.11 |
| ROE: | -347.78 | 8.70 | 73.68 |
BRIEF-GB Sciences Announces The Appointment Of John Davis As Executive VP And General Counsel
* GB SCIENCES ANNOUNCES THE APPOINTMENT OF JOHN B. DAVIS AS EXECUTIVE VP AND GENERAL COUNSEL Source text for Eikon: Further company coverage:
BRIEF-GB Sciences Pursues FDA-Registered, First-In-Human Trial Of Cannabis Based Therapy For Parkinson's Disease
* COMPANY WILL BEGIN ITS TOXICOLOGY STUDIES IN SUMMER OF 2018 Source text for Eikon: Further company coverage:
Earnings vs. 
Estimates
No consensus analysis data available.